BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.70 USD
-0.05 (-0.65%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $7.71 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCRX 7.70 -0.05(-0.65%)
Will BCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
Are Options Traders Betting on a Big Move in BCRX Stock?
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for BCRX
Is BCRX poised for a decline? Lower Bollinger Band Walk shows up after gaining 0.65%
BCRX forms Lower Bollinger Band Walk on September 15
BCRX forms Bollinger Band Squeeze on September 12
Is BCRX lining up for a decline? Death Cross shows up after climbing 0.75%
Is BCRX gaining bearish strength? Stochastic Reached Oversold shows up after dropping 0.87%